Abstract: The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of ?500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force.
Type:
Application
Filed:
November 25, 2015
Publication date:
April 14, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
Elisabeth ARKENAU-MARIC, Johannes BARTHOLOMÄUS, Heinrich KUGELMANN
Abstract: The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Type:
Grant
Filed:
August 29, 2013
Date of Patent:
April 5, 2016
Assignee:
GRÜNENTHAL GMBH
Inventors:
Stefan Schunk, Melanie Reich, Henning Steinhagen, Nils Damann, Michael Haurand, Achim Kless, Philip Skone, Richard Hamlyn, Robert Kirby, Marc Rogers, Kathy Sutton
Abstract: The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
Type:
Application
Filed:
November 19, 2015
Publication date:
March 17, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU MARIC
Abstract: The invention relates to specific carboxamides, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments.
Type:
Grant
Filed:
November 27, 2013
Date of Patent:
March 15, 2016
Assignee:
GRÜNENTHAL GMBH
Inventors:
Simon Lucas, Sven Kühnert, Gregor Bahrenberg, Wolfgang Schröder
Abstract: Substituted 6-amino-nicotinamides, pharmaceutical compositions containing these compounds and also use of these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Type:
Grant
Filed:
March 31, 2014
Date of Patent:
March 8, 2016
Assignee:
GRÜNENTHAL GMBH
Inventors:
Sven Kühnert, Gregor Bahrenberg, Achim Kless, Wolfgang Schröder, Simon Lucas
Abstract: The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of ?500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force.
Type:
Application
Filed:
November 9, 2015
Publication date:
March 3, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
Elisabeth ARKENAU MARIC, Johannes BARTHOLOMÄUS, Heinrich KUGELMANN
Abstract: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
Type:
Application
Filed:
October 15, 2015
Publication date:
February 4, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
Ingo KONETZKI, Florian JAKOB, Tobias CRAAN, Christian HESSLINGER, Paul RATCLIFFE, Antonio NARDI
Abstract: The invention relates to substituted heteroquinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Type:
Grant
Filed:
November 27, 2013
Date of Patent:
February 2, 2016
Assignee:
GRÜNENTHAL GMBH
Inventors:
Sven Kühnert, Simon Lucas, Gregor Bahrenberg, Wolfgang Schröder
Abstract: The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
Type:
Application
Filed:
October 5, 2015
Publication date:
January 28, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
Abstract: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.
Type:
Application
Filed:
October 5, 2015
Publication date:
January 28, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
Elisabeth ARKENAU MARIC, Johannes BARTHOLOMAEUS, Heinrich KUGELMANN
Abstract: The invention relates to a method for supplying at least one analysis apparatus with at least one liquid. In the method, the liquid is kept available in a storage tank, from where it is transported into at least one buffer tank. The liquid is fed to the analysis apparatus from the buffer tank, whose filling level is monitored. Here, the buffer tank is arranged above the analysis apparatus and the storage tank is arranged below the analysis apparatus. The invention also relates to a device for carrying out this method as well as to an analysis apparatus in which this device is employed.
Type:
Grant
Filed:
August 4, 2011
Date of Patent:
January 12, 2016
Assignees:
GRÜNENTHAL GMBH, NEVOLAB GMBH
Inventors:
Martin Fuhr, Stefan Oberbörsch, Martin Metzger, Manfred Lorenz
Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.
Type:
Application
Filed:
September 1, 2015
Publication date:
December 24, 2015
Applicant:
GRÜNENTHAL GMBH
Inventors:
Lutz BARNSCHEID, Eric GALIA, Sebastian SCHWIER, Ulrike BERTRAM, Anja GEISSLER, Kornelia GRIESSMANN, Johannes BARTHOLOMÄUS
Abstract: The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.
Type:
Application
Filed:
August 25, 2015
Publication date:
December 17, 2015
Applicant:
GRÜNENTHAL GMBH
Inventors:
ELISABETH ARKENAU-MARIC, JOHANNES BARTHOLOMÄUS, HEINRICH KUGELMANN
Abstract: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
Type:
Application
Filed:
August 4, 2015
Publication date:
December 10, 2015
Applicant:
GRÜNENTHAL GMBH
Inventors:
Ingo KONETZKI, Florian JAKOB, Tobias CRAAN, Christian HESSLINGER
Abstract: The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.
Type:
Grant
Filed:
January 10, 2014
Date of Patent:
December 8, 2015
Assignee:
GRÜNENTHAL GMBH
Inventors:
Sonja Nordhoff, Sebastian Wachten, Achim Kless, Felix Voss, Stefanie Ritter
Abstract: Substituted indole derivatives, processes for the preparation thereof, medicinal products and pharmaceutical compositions containing these compounds and the use of substituted indole derivatives to treat pain and other conditions and for other medical purposes.
Type:
Grant
Filed:
December 11, 2012
Date of Patent:
December 8, 2015
Assignee:
GRÜNENTHAL GMBH
Inventors:
Stefan Schunk, Stefan Oberbörsch, Werner Englberger, Bernd Sundermann
Abstract: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
Type:
Application
Filed:
August 4, 2015
Publication date:
December 3, 2015
Applicant:
GRÜNENTHAL GMBH
Inventors:
Ingo KONETZKI, Florian JAKOB, Tobias CRAAN, Christian HESSLINGER, Paul RATCLIFFE, Jason J. SHIERS
Abstract: The invention relates to an oral pharmaceutical dosage form providing resistance against dose dumping in aqueous ethanol and comprising a pharmacologically active ingredient embedded in a matrix material, wherein the matrix material comprises an alkyl cellulose and a heteropolysaccharide; and wherein the relative weight ratio of heteropolysaccharide to alkyl cellulose is within the range of from 1:20 to 20:1; and wherein the total content of alkyl cellulose and heteropolysaccharide is at least 35 wt.-%, relative to the total weight of the dosage form. A process of producing the dosage form and methods of using the dosage form, for example to treat pain, are also disclosed.
Type:
Application
Filed:
May 22, 2015
Publication date:
November 26, 2015
Applicant:
GRÜNENTHAL GMBH
Inventors:
LUTZ BARNSCHEID, KLAUS WENING, JANA PÄTZ, ANJA GEISSLER
Abstract: The invention is directed to an immediate release capsule which mitigates the abuse of Tapentadol or physiologically acceptable salt thereof by direct intravenous injection. The capsule comprises a tamper resistant formulation which when mixed with water and heated, results in a turbid, bubbling mixture that is not injectable with a standard insulin syringe.
Type:
Application
Filed:
May 11, 2015
Publication date:
November 12, 2015
Applicant:
GRÜNENTHAL GMBH
Inventors:
Ingo FRIEDRICH, Richard FUHRHERR, Silke MÖSCHTER, Simone WENGNER
Abstract: The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with potential for abuse (A), at least one synthetic or natural polymer (C), optionally delayed-release matrix auxiliary substances, physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
Type:
Application
Filed:
July 10, 2015
Publication date:
November 5, 2015
Applicant:
GRÜNENTHAL GMBH
Inventors:
Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC